FindTrial
Sign In

The effectiveness of vitrecomy co-adjuvant intravitreal dexamethasone implant for rehegmatougenous retinal detachment combined with choroidal detachment

The effectiveness of vitrecomy co-adjuvant intravitreal dexamethasone implant for rehegmatougenous retinal detachment combined with choroidal detachment

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200060427
Enrollment
Unknown
Registered
2022-06-01
Start date
2022-05-20
Completion date
Unknown
Last updated
2024-05-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

rehegmatougenous retinal detachment combined with choroidal detachment

Interventions

Group A:vitrecomy co-adjuvant intravitreal dexamethasone implant
Group B:vitrectomy

Sponsors

Beijing Tongren Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. The eye with a diagnosis of rehegmatougenous retinal detachment combined with choroidal detachment; 2. Aged between 18-70 years; 3. Admit to join the research and follow the follow-up plan.

Exclusion criteria

Exclusion criteria: 1. The general condition is too severe to undergo vitrectomy; 2. Past vitrectomy; 3. Previous history of glaucoma; 4. History of uveitis; 5. Lens subluxation, aphenoid eye or intraocular lens deviation; 6. Blunt eye trauma or perforating injury combined with retinal choroid injury; 7. Congenital abnormalities of retinal choroid development.

Design outcomes

Primary

MeasureTime frame
visual acuity;macular retinal thickness;retinal attachment;—

Secondary

MeasureTime frame
the dose of steroid;—

Countries

China

Contacts

Public ContactLi Jipeng

Beijing Tongren Eye Center

jipeng2004@sina.com+86 13910998208

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026